```
=> dis his nofile;d l3 que stat;file caplus;s l3

     (FILE 'HOME' ENTERED AT 15:09:41 ON 26 SEP 2007)

     FILE 'REGISTRY' ENTERED AT 15:09:49 ON 26 SEP 2007
L1               STR
L2             1 SEA SSS SAM L1
L3            37 SEA SSS FUL L1


L1               STR
```



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  22

STEREO ATTRIBUTES: NONE
L3            37 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED     121 ITERATIONS                                37 ANSWERS
SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 15:12:13 ON 26 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 26 Sep 2007  VOL 147 ISS 14
FILE LAST UPDATED: 25 Sep 2007  (20070925/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
```

L4 1 L3

=> d ibib abs hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:588963 CAPLUS Full-text
DOCUMENT NUMBER: 143:115560
TITLE: Preparation of pyrido[2,3-d]pyrimidine-2,4-diamines as PDE-2 inhibitors
INVENTOR(S): Beyer, Thomas Arthur; Chambers, Robert James; Lam, Kelvin; Li, Mei; Morrell, Andrew Ian; Thompson, David Duane
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005061497	A1	20050707	WO 2004-IB4013		20041206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004303609	A1	20050707	AU 2004-303609		20041206
CA 2549510	A1	20050707	CA 2004-2549510		20041206
EP 1697356	A1	20060906	EP 2004-801323		20041206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU					
CN 1894245	A	20070110	CN 2004-80037674		20041206
BR 2004017663	A	20070403	BR 2004-17663		20041206
JP 2007513996	T	20070531	JP 2006-544574		20041206
NL 1027787	A1	20050621	NL 2004-1027787		20041215
NL 1027787	C2	20060309			
US 2007135457	A1	20070614	US 2006-595766		20060510
IN 2006DN02850	A	20070810	IN 2006-DN2850		20060519
MX 2006PA06777	A	20060823	MX 2006-PA6777		20060615
NO 2006003231	A	20060711	NO 2006-3231		20060711
PRIORITY APPLN. INFO.:			US 2003-529994P	P	20031216
			WO 2004-IB4013	W	20041206

GI



I

II



III

AB Title compds. I [Z = O-alkyl; R1, R2 = H, OCH3 with provisos; n = 1-4; X = a bond, O, S, etc.; Y = benzoxazolyl, benzothiazolyl, benzofurazanyl, etc.] and their pharmaceutically acceptable salts were prepared For example, aminoarom. substitution of chloropyrimide II and 2-(2-aminoethyl)pyridine afforded pyrido[2,3-d]pyrimidine III in 40% yield. In PDE 2 inhibition assays, 4 - examples of compds. I exhibited IC50 values <50 nM.

IT 857521-01-8P 857521-02-9P 857521-03-0P
857521-04-1P 857521-05-2P 857521-06-3P
857521-07-4P 857521-08-5P 857521-09-6P
857521-10-9P 857521-11-0P 857521-12-1P
857521-13-2P 857521-14-3P 857521-15-4P
857521-16-5P 857521-17-6P 857521-18-7P
857521-19-8P 857521-20-1P 857521-21-2P
857521-22-3P 857521-23-4P 857521-24-5P
857521-25-6P 857521-26-7P 857521-27-8P
857521-28-9P 857521-29-0P 857521-30-3P
857521-31-4P 857521-32-5P 857521-33-6P
857521-34-7P 857521-35-8P 857521-36-9P
857521-37-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrido[2,3-d]pyrimidine-2,4-diamines as PDE-2 inhibitors)

RN 857521-01-8 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 857521-02-9 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)



RN 857521-03-0 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 857521-04-1 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 857521-05-2 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N,N'-bis[(3,5-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 857521-06-3 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)



RN 857521-07-4 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(3-phenylpropyl)- (CA INDEX NAME)



RN 857521-08-5 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[(4-chlorophenyl)methyl]-N4-[(3,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-09-6 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(phenylmethyl)- (CA INDEX NAME)



RN 857521-10-9 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(2-thienyl)ethyl]- (CA INDEX NAME)



RN 857521-11-0 CAPLUS
CN Benzenemethanol, 4-[[[4-[[(3,5-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]methyl]-α,α-dimethyl- (CA INDEX NAME)



RN 857521-12-1 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(2-phenylethyl)- (CA INDEX NAME)



RN 857521-13-2 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[2-(3,5-dimethoxyphenyl)ethyl]-N4-[(3,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-14-3 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[2-(3-fluorophenyl)ethyl]- (CA INDEX NAME)



RN 857521-15-4 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[2-(2-fluorophenyl)ethyl]- (CA INDEX NAME)



RN 857521-16-5 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[2-(4-fluorophenyl)ethyl]- (CA INDEX NAME)



RN 857521-17-6 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(2-phenylethyl)- (CA INDEX NAME)



RN 857521-18-7 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(4-phenylbutyl)- (CA INDEX NAME)



RN 857521-19-8 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(2-phenoxyethyl)- (CA INDEX NAME)



RN 857521-20-1 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 857521-21-2 CAPLUS
CN Benzenemethanol, 4-[2-[[4-[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]-α,α-dimethyl- (CA INDEX NAME)



RN 857521-22-3 CAPLUS
CN Benzenemethanol, 4-[2-[[4-[[(3,5-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]-α,α-dimethyl- (CA INDEX NAME)



RN 857521-23-4 CAPLUS
CN Benzenemethanol, 4-[[[4-[[(3,5-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]methyl]-α-(trifluoromethyl)- (CA INDEX NAME)



RN 857521-24-5 CAPLUS
CN Ethanone, 1-[4-[3-[[4-[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]phenyl]- (CA INDEX NAME)



RN 857521-25-6 CAPLUS
CN Benzenemethanol, 4-[3-[[4-[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]-α-(trifluoromethyl)- (CA INDEX NAME)



RN 857521-26-7 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[3-(2,1,3-benzoxadiazol-5-yl)propyl]-N4-[(3,4-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-27-8 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[3-(6-benzothiazolyl)propyl]-N4-[(3,4-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-28-9 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[3-[3-(2-methyl-1,3-dioxolan-2-yl)phenyl]propyl]- (CA INDEX NAME)



RN 857521-29-0 CAPLUS
CN Benzenemethanol, 3-[3-[[4-[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]-α-methyl- (CA INDEX NAME)



RN 857521-30-3 CAPLUS
CN Benzonitrile, 4-[3-[[4-[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]- (CA INDEX NAME)



RN 857521-31-4 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[3-(4-pyridinyl)propyl]- (CA INDEX NAME)



RN 857521-32-5 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(3-phenylpropyl)- (CA INDEX NAME)



RN 857521-33-6 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(3-phenoxypropyl)- (CA INDEX NAME)



RN 857521-34-7 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3-ethoxy-4-methoxyphenyl)methyl]-N2-(3-phenylpropyl)- (CA INDEX NAME)



RN 857521-35-8 CAPLUS
CN Benzenemethanol, 4-[3-[[4-[[(3-ethoxy-4-methoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]-α-methyl- (CA INDEX NAME)



RN 857521-36-9 CAPLUS
CN Ethanone, 1-[4-[3-[[4-[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 857521-37-0 CAPLUS
CN Ethanone, 1-[3-[3-[[4-[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-

d]pyrimidin-2-yl]amino]propyl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil medl,biosis,embase,caplus;s beyer t?/au;s chambers r?/au;s lam k?/au;s westerly m?/au;s morrell a?/au;s thompson d?/au

FILE 'MEDLINE' ENTERED AT 15:13:22 ON 26 SEP 2007

FILE 'BIOSIS' ENTERED AT 15:13:22 ON 26 SEP 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 15:13:22 ON 26 SEP 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 15:13:22 ON 26 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

L5 188 FILE MEDLINE
L6 247 FILE BIOSIS
L7 168 FILE EMBASE
L8 158 FILE CAPLUS

TOTAL FOR ALL FILES
L9 761 BEYER T?/AU

L10 483 FILE MEDLINE
L11 713 FILE BIOSIS
L12 354 FILE EMBASE
L13 1052 FILE CAPLUS

TOTAL FOR ALL FILES
L14 2602 CHAMBERS R?/AU

L15 1469 FILE MEDLINE
L16 1572 FILE BIOSIS
L17 1315 FILE EMBASE
L18 1264 FILE CAPLUS

```
TOTAL FOR ALL FILES
L19       5620 LAM K?/AU

  NOTE (l20-l24 deleted)


L25         53 FILE MEDLINE
L26         67 FILE BIOSIS
L27         64 FILE EMBASE
L28         53 FILE CAPLUS

TOTAL FOR ALL FILES
L29        237 MORRELL A?/AU


L30       2948 FILE MEDLINE
L31       3971 FILE BIOSIS
L32       2212 FILE EMBASE
L33       4092 FILE CAPLUS

TOTAL FOR ALL FILES
L34      13223 THOMPSON D?/AU

=> s l9 and l14 and l19 and l29 and l34;s li m?/au
L35          0 FILE MEDLINE
L36          0 FILE BIOSIS
L37          0 FILE EMBASE
L38          1 FILE CAPLUS

TOTAL FOR ALL FILES
L39          1 L9 AND L14 AND L19 AND L29 AND L34


L40       4567 FILE MEDLINE
L41       5087 FILE BIOSIS
L42       3613 FILE EMBASE
L43      15811 FILE CAPLUS

TOTAL FOR ALL FILES
L44      29078 LI M?/AU

=> s l44 and l39
L45          0 FILE MEDLINE
L46          0 FILE BIOSIS
L47          0 FILE EMBASE
L48          1 FILE CAPLUS

TOTAL FOR ALL FILES
L49          1 L44 AND L39

=> s l49 not l4
L50          0 FILE MEDLINE
L51          0 FILE BIOSIS
L52          0 FILE EMBASE
L53          0 FILE CAPLUS

TOTAL FOR ALL FILES
L54          0 L49 NOT L4
```

```
=> s l4
L55           0 FILE MEDLINE
L56           0 FILE BIOSIS
L57           0 FILE EMBASE
L58           1 FILE CAPLUS

TOTAL FOR ALL FILES
L59           1 L4

=> fil reg;e "pyrido[2,3-d]pyrimidine-2,4-diamine"/cn 5

FILE 'REGISTRY' ENTERED AT 15:14:49 ON 26 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 SEP 2007  HIGHEST RN 948051-90-9
DICTIONARY FILE UPDATES:  25 SEP 2007  HIGHEST RN 948051-90-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html


E1            1     PYRIDIUM, 4-STYRYL-1-VINYL-/CN
E2            1     PYRIDIUM, 4-STYRYL-1-VINYL-, P-TOLUENESULFONATE/CN
E3            0 --> PYRIDO2,3-DPYRIMIDINE-2,4-DIAMINE/CN
E4            1     PYRIDO(1''',2''':1'',2'')IMIDAZO(4'',5'':3',4')CYCLOPENTA(1'
                    ,2':5,6)NAPHTH(1,2-D)AZEPIN-2(3H)-ONE, 4,5,5A,5B,6,7,7A,14,1
                    4A,14B,15,16-DODECAHYDRO-5A,7A,10-TRIMETHYL-, (5AR-(5A.ALPHA
                    .,5BB,7AA/CN
E5            1     PYRIDO(1''',2''':1'',2'')IMIDAZO(4'',5'':3',4')CYCLOPENTA(1'
                    ,2':5,6)NAPHTH(1,2-D)AZEPIN-2(3H)-ONE, 4,5,5A,5B,6,7,7A,14,1
                    4A,14B,15,16-DODECAHYDRO-5A,7A,11-TRIMETHYL-, (5AR-(5A.ALPHA
                    .,5BB,7AA/CN

=> s pyrido(l)pyrimidine(l)diamine
        273116 PYRIDO
        619275 PYRIMIDINE
        358987 DIAMINE
            74 DIAMINES
        358987 DIAMINE
                  (DIAMINE OR DIAMINES)
L60       1433 PYRIDO(L)PYRIMIDINE(L)DIAMINE

=> fil medl,biosis,embase,caplus;s l60 or pyrido(7a)pyrimidine(5a)diamine
```

```
FILE 'MEDLINE' ENTERED AT 15:16:39 ON 26 SEP 2007

FILE 'BIOSIS' ENTERED AT 15:16:39 ON 26 SEP 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 15:16:39 ON 26 SEP 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 15:16:39 ON 26 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


L61          90 FILE MEDLINE
L62         156 FILE BIOSIS
L63         380 FILE EMBASE
L64         478 FILE CAPLUS

TOTAL FOR ALL FILES
L65        1104 L60 OR PYRIDO(7A) PYRIMIDINE(5A) DIAMINE

=> s pde2 or phosphodiesterase
L66       26278 FILE MEDLINE
L67       24560 FILE BIOSIS
L68       26236 FILE EMBASE
L69       27972 FILE CAPLUS

TOTAL FOR ALL FILES
L70      105046 PDE2 OR PHOSPHODIESTERASE

=> s l65 and l70
L71           0 FILE MEDLINE
L72           0 FILE BIOSIS
L73           0 FILE EMBASE
L74           6 FILE CAPLUS

TOTAL FOR ALL FILES
L75           6 L65 AND L70

=> d 1-6 ibib abs hitstr

L75  ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2007:173503  CAPLUS  Full-text
DOCUMENT NUMBER:          146:229376
TITLE:                    Preparation of fused pyridofuropyrimidines as
                          phosphodiesterase 4 (PDE4) inhibitors.
INVENTOR(S):              Taltavull Moll, Joan; Pages Santacana, Luis Miquel
PATENT ASSIGNEE(S):       Almirall Prodesfarma, S. A., Spain
SOURCE:                   PCT Int. Appl., 61pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2007017078         A1    20070215    WO 2006-EP7218          20060721
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
```

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

ES 2281251 A1 20070916 ES 2005-1840 20050727

PRIORITY APPLN. INFO.: ES 2005-1840 A 20050727

OTHER SOURCE(S): MARPAT 146:229376

GI



I

AB Title compds. [I; G1 = CR6R7, O; R6, R7 = H, alkyl; R1, R2 = H, alkyl; R3 = (substituted) alkyl, alkoxy, amino, OH, alkylamino, dialkylamino, cycloalkylamino, aryl, heteroaryl, saturated N-bonded heterocyclyl; R4, R5 = H, alkyl, hydroxyalkyl, etc.], were prepared Thus, N5-isopropyl-2,2-dimethyl-N8-(2-morpholin-4-ylethyl)-1,2,3,4-tetrahydropyrimido[4',5':4,5]furo[2,3-c]isoquinoline-5,8-diamine (preparation outlined) inhibited PDE4 with IC50 = 0.2 nM.

IT 925214-07-9P 925214-08-0P 925214-09-1P 925214-11-5P 925214-12-6P 925214-43-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused pyridofuropyrimidines as PDE4 inhibitors)

RN 925214-07-9 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]furo[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,N5,2,2-tetramethyl-N8-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 925214-08-0 CAPLUS
CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]furo[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,N5,2,2-tetramethyl-N8-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 925214-09-1 CAPLUS
CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]furo[3,2-d]pyrimidine-5,8-diamine, N8-[(2,3-dimethoxyphenyl)methyl]-1,4-dihydro-N5,N5,2,2-tetramethyl- (CA INDEX NAME)



RN 925214-11-5 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]furo[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,N5,2,2-tetramethyl-N8-[2-(4-morpholinyl)ethyl]-N8-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 925214-12-6 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]furo[3,2-d]pyrimidine-5,8-diamine, N8-[(3,4-dimethoxyphenyl)methyl]-1,4-dihydro-N5,N5,2,2-tetramethyl- (CA INDEX NAME)



RN 925214-43-3 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]furo[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,2,2-trimethyl-N8-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



IT 925214-72-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused pyridofuropyrimidines as PDE4 inhibitors)
RN 925214-72-8 CAPLUS
CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]furo[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,2,2-trimethyl-N8-[2-(4-morpholinyl)ethyl]-N5-(phenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L75 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:542483 CAPLUS Full-text
DOCUMENT NUMBER: 145:28003
TITLE: New pyridothienopyrimidine derivatives, their preparation and use as PDE4 inhibitors for the treatment of pathological diseases
INVENTOR(S): Pages Santacana, Luis Miquel; Taltavull Moll, Joan; Gracia Ferrer, Jordi
PATENT ASSIGNEE(S): Almirall Prodesfarma, S.A., Spain
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006058723	A1	20060608	WO 2005-EP12773	20051130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
ES 2259892	A1	20061016	ES 2004-2877	20041130
AU 2005311422	A1	20060608	AU 2005-311422	20051130
CA 2588808	A1	20060608	CA 2005-2588808	20051130
EP 1819712	A1	20070822	EP 2005-813317	20051130
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

PRIORITY APPLN. INFO.: ES 2004-2877 A 20041130
WO 2005-EP12773 W 20051130

OTHER SOURCE(S): MARPAT 145:28003
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is related to the use of a pyrido[3',2':4,5]thieno[3,2-d]pyrimidine derivative I [X = (CH2)n; n = 0-1; R1, R2 = independently H , alkyl; R3 = (un)substituted alkyl, monoalkyl/dialkyl/amino, hetero/aryl, etc.; R4, R5 = independently H, alkyl, -(CR8R9)p-A-(CR10R11)q-G2; p, q = independently 1-3; A = a bond, O, OCO , etc.; R8-R11 = independently H, alkyl; G2 = (un)substituted hetero/aryl, heterocyclyl] and their pharmaceutically acceptable salts and N-oxides, in the manufacture of a medicament for the treatment or prevention of a pathol. condition or disease susceptible to amelioration by inhibition of Phosphodiesterase 4 (PDE4). The invention is also related to the preparation of pyridothienopyrimidines I. Four pharmaceutical compns. are given. For example, II was prepared by cyclocondensation of thiopyridine III (preparation given) with 2-chloroacetamide, cyclization with Et orthoformate, chlorination, and amination of chloride with 4-pyridinemethanamine. Preferred I exhibited an IC50 value < 30 nM for the inhibition of PDE4. I and their pharmaceutical compns. are useful for prevention and treatment of asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis and irritable bowel disease (no data).

IT 889657-27-6P 889657-28-7P 889657-49-2P
889657-50-5P 889657-51-6P 889657-52-7P
889657-53-8P 889657-54-9P 889657-70-9P
889657-71-0P 889657-73-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyridothienopyrimidines as PDE4 inhibitors for treating pathol. diseases)

RN 889657-27-6 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N-(2-methoxyethyl)-N,2,2-trimethyl-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 889657-28-7 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N-(2-methoxyethyl)-N,2,2-trimethyl-N'-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 889657-49-2 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N,N,2,2-tetramethyl-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 889657-50-5 CAPLUS
CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N,N,2,2-tetramethyl-N'-[3-(4-morpholinyl)propyl]-(9CI) (CA INDEX NAME)



RN 889657-51-6 CAPLUS
CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, N8-[(2,3-dimethoxyphenyl)methyl]-1,4-dihydro-N5,N5,2,2-tetramethyl- (CA INDEX NAME)



RN 889657-52-7 CAPLUS
CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,N5,2,2-tetramethyl-N8-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 889657-53-8 CAPLUS
CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,N5,2,2-tetramethyl-N8-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 889657-54-9 CAPLUS
CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,N5,2,2-tetramethyl-N8-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 889657-70-9 CAPLUS
CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,2,2-trimethyl-N8-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 889657-71-0 CAPLUS
CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,2,2-trimethyl-N8-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 889657-73-2 CAPLUS
CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-

diamine, 1,4-dihydro-N5,2,2-trimethyl-N8-[2-(4-morpholinyl)ethyl]-N8-(3-pyridinylmethyl)- (CA INDEX NAME)



IT 889656-87-5P 889656-88-6P 889656-90-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyridothienopyrimidines as PDE4 inhibitors for
treating pathol. diseases)

RN 889656-87-5 CAPLUS
CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N,2,2-trimethyl-N'-[2-(4-morpholinyl)ethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 889656-88-6 CAPLUS
CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N,2,2-trimethyl-N-(phenylmethyl)-N'-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 889656-90-0 CAPLUS
CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N,2,2-trimethyl-N'-[2-(4-morpholinyl)ethyl]-N-(phenylmethyl)-N'-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L75 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:539368 CAPLUS Full-text
DOCUMENT NUMBER: 145:46072
TITLE: New pyridothienopyrimidine derivatives, their preparation and use as PDE4 inhibitors for the treatment of pathological diseases
INVENTOR(S): Pages Santacana, Lluis Miquel; Taltavull Moll, Joan
PATENT ASSIGNEE(S): Almirall Prodesfarma, S.A., Spain
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006058724	A1	20060608	WO 2005-EP12774	20051130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,				

```
            KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
            MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
            SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
            VN, YU, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
    ES 2259891          A1    20061016    ES 2004-2876          20041130
    AU 2005311423       A1    20060608    AU 2005-311423        20051130
    CA 2588741          A1    20060608    CA 2005-2588741       20051130
    EP 1819710          A1    20070822    EP 2005-814833        20051130
        R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
            BA, HR, MK, YU
    IN 2007DN03938      A     20070831    IN 2007-DN3938        20070525
PRIORITY APPLN. INFO.:                    ES 2004-2876       A  20041130
                                          WO 2005-EP12774    W  20051130

OTHER SOURCE(S):        MARPAT 145:46072
GI
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is related to the use of a pyridothienopyrimidine derivative I [X = (G1)m; G1 = CR6R7, NR6; R6, R7 = independently H, alkyl; Y = (CH2)n; m, n = independently 0-1; R1, R2 = independently H , alkyl; R3 = (un)substituted alkyl, monoalkyl/dialkyl/amino, hetero/aryl, etc.; R4, R5 = independently H, alkyl, -(CR8R9)p-A-(CR10R11)q-G2; p, q = independently 1-3; A = a bond, O, OCO , etc.; R8-R11 = independently H, alkyl; G2 = (un)substituted hetero/aryl, heterocyclyl], and their pharmaceutically acceptable salts and N-oxides, in the manufacture of a medicament for the treatment or prevention of a pathol. condition or disease susceptible to amelioration by inhibition of Phosphodiesterase 4 (PDE4). The invention is also related to the preparation of pyridothienopyrimidines I. Four pharmaceutical compns. are given. For example, II was prepared by cyclocondensation of thiopyridine III with 2-chloroacetamide, cyclization with Et orthoformate, chlorination, and amination of the chloride with [2-(morpholin-4-yl)ethyl]amine. Preferred I exhibited an IC50 value < 30 nM for the inhibition of PDE4. I and their pharmaceutical compns. are useful for prevention and treatment of asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis and irritable bowel disease (no data).

IT 890024-43-8P 890024-44-9P 890024-46-1P
890024-48-3P 890024-49-4P 890024-52-9P
890024-53-0P 890024-54-1P 890024-64-3P
890024-66-5P 890024-68-7P 890024-71-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyridothienopyrimidines as PDE4 inhibitors for treating pathol. diseases)

RN 890024-43-8 CAPLUS

CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine, 2,3-dihydro-N4,N4,2,2-tetramethyl-N7-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 890024-44-9 CAPLUS
CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine, 2,3-dihydro-N4,N4,2,2-tetramethyl-N7-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 890024-46-1 CAPLUS
CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine, N7-(2-furanylmethyl)-2,3-dihydro-N4,N4,2,2-tetramethyl- (CA INDEX NAME)



RN 890024-48-3 CAPLUS
CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine, 2,3-dihydro-N4,N4,1,1-tetramethyl-N7-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 890024-49-4 CAPLUS
CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine, 2,3-dihydro-N4,N4,1,1-tetramethyl-N7-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 890024-52-9 CAPLUS
CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine, 2,3-dihydro-N7-[2-(1H-imidazol-4-yl)ethyl]-N4,N4,1,1-tetramethyl- (9CI) (CA INDEX NAME)



RN 890024-53-0 CAPLUS

CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine, N7-(2-furanylmethyl)-2,3-dihydro-N4,N4,1,1-tetramethyl- (CA INDEX NAME)



RN 890024-54-1 CAPLUS

CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine, N7-[(2,3-dimethoxyphenyl)methyl]-2,3-dihydro-N4,N4,1,1-tetramethyl- (CA INDEX NAME)



RN 890024-64-3 CAPLUS

CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine, N-ethyl-2,3-dihydro-N,2,2-trimethyl-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 890024-66-5 CAPLUS
CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine, N-ethyl-2,3-dihydro-N,2,2-trimethyl-N'-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 890024-68-7 CAPLUS
CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine, N'-[(2,3-dimethoxyphenyl)methyl]-N-ethyl-2,3-dihydro-N,2,2-trimethyl- (9CI) (CA INDEX NAME)



RN 890024-71-2 CAPLUS
CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine, N4-ethyl-2,3-dihydro-N4,2,2-trimethyl-N7-[2-(4-morpholinyl)ethyl]-N7-(3-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L75 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:588963 CAPLUS Full-text
DOCUMENT NUMBER: 143:115560
TITLE: Preparation of pyrido[2,3-d] pyrimidine-2,4-diamines as PDE-2 inhibitors
INVENTOR(S): Beyer, Thomas Arthur; Chambers, Robert James; Lam, Kelvin; Li, Mei; Morrell, Andrew Ian; Thompson, David Duane
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061497	A1	20050707	WO 2004-IB4013	20041206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303609	A1	20050707	AU 2004-303609	20041206
CA 2549510	A1	20050707	CA 2004-2549510	20041206
EP 1697356	A1	20060906	EP 2004-801323	20041206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1894245	A	20070110	CN 2004-80037674	20041206
BR 2004017663	A	20070403	BR 2004-17663	20041206
JP 2007513996	T	20070531	JP 2006-544574	20041206
NL 1027787	A1	20050621	NL 2004-1027787	20041215
NL 1027787	C2	20060309		

US 2007135457	A1	20070614	US 2006-595766		20060510
IN 2006DN02850	A	20070810	IN 2006-DN2850		20060519
MX 2006PA06777	A	20060823	MX 2006-PA6777		20060615
NO 2006003231	A	20060711	NO 2006-3231		20060711
PRIORITY APPLN. INFO.:			US 2003-529994P	P	20031216
			WO 2004-IB4013	W	20041206

GI



I II III

AB Title compds. I [Z = O-alkyl; R1, R2 = H, OCH3 with provisos; n = 1-4; X = a bond, O, S, etc.; Y = benzoxazolyl, benzothiazolyl, benzofurazanyl, etc.] and their pharmaceutically acceptable salts were prepared For example, aminoarom. substitution of chloropyrimide II and 2-(2-aminoethyl)pyridine afforded pyrido[2,3-d]pyrimidine III in 40% yield. In PDE 2 inhibition assays, 4 - examples of compds. I exhibited IC50 values <50 nM.

IT 857521-01-8P 857521-02-9P 857521-03-0P
857521-04-1P 857521-05-2P 857521-06-3P
857521-07-4P 857521-08-5P 857521-09-6P
857521-10-9P 857521-12-1P 857521-13-2P
857521-14-3P 857521-15-4P 857521-16-5P
857521-17-6P 857521-18-7P 857521-19-8P
857521-20-1P 857521-26-7P 857521-27-8P
857521-28-9P 857521-31-4P 857521-32-5P
857521-33-6P 857521-34-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrido[2,3-d]pyrimidine-2,4-diamines as PDE-2 inhibitors)

RN 857521-01-8 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 857521-02-9 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)



RN 857521-03-0 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 857521-04-1 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 857521-05-2 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N,N'-bis[(3,5-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 857521-06-3 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)



RN 857521-07-4 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(3-phenylpropyl)- (CA INDEX NAME)



RN 857521-08-5 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[(4-chlorophenyl)methyl]-N4-[(3,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-09-6 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(phenylmethyl)- (CA INDEX NAME)



RN 857521-10-9 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(2-thienyl)ethyl]- (CA INDEX NAME)



RN 857521-12-1 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(2-phenylethyl)- (CA INDEX NAME)



RN 857521-13-2 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[2-(3,5-dimethoxyphenyl)ethyl]-N4-[(3,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-14-3 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[2-(3-fluorophenyl)ethyl]- (CA INDEX NAME)



RN 857521-15-4 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[2-(2-fluorophenyl)ethyl]- (CA INDEX NAME)



RN 857521-16-5 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[2-(4-fluorophenyl)ethyl]- (CA INDEX NAME)



RN 857521-17-6 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(2-phenylethyl)- (CA INDEX NAME)



RN 857521-18-7 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(4-phenylbutyl)- (CA INDEX NAME)



RN 857521-19-8 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(2-phenoxyethyl)- (CA INDEX NAME)



RN 857521-20-1 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 857521-26-7 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[3-(2,1,3-benzoxadiazol-5-yl)propyl]-N4-[(3,4-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-27-8 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[3-(6-benzothiazolyl)propyl]-N4-[(3,4-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-28-9 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[3-[3-(2-methyl-1,3-dioxolan-2-yl)phenyl]propyl]- (CA INDEX NAME)



RN 857521-31-4 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[3-(4-pyridinyl)propyl]- (CA INDEX NAME)



RN 857521-32-5 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(3-phenylpropyl)- (CA INDEX NAME)



RN 857521-33-6 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(3-phenoxypropyl)- (CA INDEX NAME)



RN 857521-34-7 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3-ethoxy-4-methoxyphenyl)methyl]-N2-(3-phenylpropyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L75 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:563288 CAPLUS Full-text
DOCUMENT NUMBER: 139:307967
TITLE: New Base Pairing Motifs. The Synthesis and Thermal Stability of Oligodeoxynucleotides Containing Imidazopyridopyrimidine Nucleosides with the Ability to Form Four Hydrogen Bonds
AUTHOR(S): Minakawa, Noriaki; Kojima, Naoshi; Hikishima, Sadao; Sasaki, Takashi; Kiyosue, Arihiro; Atsumi, Naoko; Ueno, Yoshihito; Matsuda, Akira
CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, 060-0812, Japan
SOURCE: Journal of the American Chemical Society (2003), 125(33), 9970-9982
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:307967
AB The synthesis and thermal stability of oligodeoxynucleotides (ODNs) containing imidazo[5',4':4,5]pyrido[2,3-d]pyrimidine nucleosides 1-4 (NN, OO, NO, and ON, resp.) with the aim of developing two sets of new base pairing motifs consisting of four hydrogen bonds (H-bonds) is described. The proposed four tricyclic nucleosides were synthesized through the Stille coupling reaction of a 5-iodoimidazole nucleoside with an appropriate 5-stannylpyrimidine derivative, followed by an intramol. cyclization. These nucleosides were

incorporated into ODNs to investigate the H-bonding ability. When one mol. of the tricyclic nucleosides was incorporated into the center of each 17mer ODNs, no apparent specificity of base pairing was observed, and all duplexes were less stable than the duplexes containing natural G:C and A:T pairs. On the other hand, when three mols. of the tricyclic nucleosides were consecutively incorporated into the center of each 17mer ODNs, thermal and thermodn. stabilization of the duplexes due to the specific base pairings was observed The melting temperature (Tm) of the duplex containing the NO:ON pairs showed the highest Tm of 84.0 °C, which was 18.2 and 23.5 °C higher than that of the duplexes containing G:C and A:T pairs, resp. This result implies that NO and ON form base pairs with four H-bonds when they are incorporated into ODNs. The duplex containing NO:ON pairs was markedly stabilized by the assistance of the stacking ability of the imidazopyridopyrimidine bases. Thus, we developed a thermally stable new base pairing motif, which should be useful for the stabilization and regulation of a variety of DNA structures.

IT 597551-46-7P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (synthesis and thermal stability of oligodeoxyribonucleotides containing imidazopyridopyrimidine nucleosides with ability to form four hydrogen bonds)

RN 597551-46-7 CAPLUS

CN 1H-Imidazo[4',5':4,5]pyrido[2,3-d]pyrimidine-4,7(5H,6H)-dione, 1-[2-deoxy-3,5-bis-O-[tris(1-methylethyl)silyl]-β-D-erythro-pentofuranosyl]-, compd. with 1-[2-deoxy-3,5-bis-O-[tris(1-methylethyl)silyl]-β-D-erythro-pentofuranosyl]-1H-imidazo[4',5':4,5]pyrido[2,3-d]pyrimidine-4,7-diamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 597551-36-5
CMF C31 H53 N5 O5 Si2

Absolute stereochemistry.



CM 2

CRN 597551-28-5
CMF C31 H55 N7 O3 Si2

Absolute stereochemistry.



IT 597551-28-5P 597551-30-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and thermal stability of oligodeoxyribonucleotides containing imidazopyridopyrimidine nucleosides with ability to form four hydrogen bonds)
RN 597551-28-5 CAPLUS
CN 1H-Imidazo[4',5':4,5]pyrido[2,3-d]pyrimidine-4,7-diamine, 1-[2-deoxy-3,5-bis-O-[tris(1-methylethyl)silyl]-β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597551-30-9 CAPLUS
CN 1H-Imidazo[4',5':4,5]pyrido[2,3-d]pyrimidine-4,7-diamine, 1-(2-deoxy-β-D-erythro-pentofuranosyl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L75 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:124400 CAPLUS Full-text
DOCUMENT NUMBER: 120:124400
TITLE: Chemical synthesis of new pyridine derivatives acting as inhibitors of phosphodiesterase
AUTHOR(S): Pallas, M.; Jimenez, A.; Victory, P.; Borrell, J. I.; Vidal-Ferran, A.; Escubedo, E.; Camarasa, J.
CORPORATE SOURCE: Fac. Pharm., Univ. Barcelona, Barcelona, E-08028, Spain
SOURCE: Pharmaceutical and Pharmacological Letters (1993), 3(1), 36-9
CODEN: PPLEE3; ISSN: 0939-9488
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The chemical synthesis of new pyridine derivs. and their pharmacol. activity as inhibitors of phosphodiesterase are reported. Among them IQS-4 was the most potent inhibitor (IC50 5.8 μM) and this effect has a good correlation with a relaxant effect on carbachol-contracted guinea-pig trachea (IC50 73.4 μM). A preferential effect of these compds. on phosphodiesterase type IV was deduced are reported.

IT 20732-44-9P, IQS 2
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and phosphodiesterase inhibitory activity of)

RN 20732-44-9 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4-diamine, 5,7-diphenyl- (9CI) (CA INDEX NAME)



=> dis his nofile

(FILE 'HOME' ENTERED AT 15:09:41 ON 26 SEP 2007)

FILE 'REGISTRY' ENTERED AT 15:09:49 ON 26 SEP 2007
L1 STR
L2 1 SEA SSS SAM L1
L3 37 SEA SSS FUL L1
D L3 QUE STAT

```
     FILE 'CAPLUS' ENTERED AT 15:12:13 ON 26 SEP 2007
L4             1 SEA ABB=ON  PLU=ON  L3
                 D IBIB ABS HITSTR

     FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 15:13:22 ON 26 SEP 2007
L5           188 SEA ABB=ON  PLU=ON  BEYER T?/AU
L6           247 SEA ABB=ON  PLU=ON  BEYER T?/AU
L7           168 SEA ABB=ON  PLU=ON  BEYER T?/AU
L8           158 SEA ABB=ON  PLU=ON  BEYER T?/AU
     TOTAL FOR ALL FILES
L9           761 SEA ABB=ON  PLU=ON  BEYER T?/AU
L10          483 SEA ABB=ON  PLU=ON  CHAMBERS R?/AU
L11          713 SEA ABB=ON  PLU=ON  CHAMBERS R?/AU
L12          354 SEA ABB=ON  PLU=ON  CHAMBERS R?/AU
L13         1052 SEA ABB=ON  PLU=ON  CHAMBERS R?/AU
     TOTAL FOR ALL FILES
L14         2602 SEA ABB=ON  PLU=ON  CHAMBERS R?/AU
L15         1469 SEA ABB=ON  PLU=ON  LAM K?/AU
L16         1572 SEA ABB=ON  PLU=ON  LAM K?/AU
L17         1315 SEA ABB=ON  PLU=ON  LAM K?/AU
L18         1264 SEA ABB=ON  PLU=ON  LAM K?/AU
     TOTAL FOR ALL FILES
L19         5620 SEA ABB=ON  PLU=ON  LAM K?/AU
  L20-L24 deleted
L25           53 SEA ABB=ON  PLU=ON  MORRELL A?/AU
L26           67 SEA ABB=ON  PLU=ON  MORRELL A?/AU
L27           64 SEA ABB=ON  PLU=ON  MORRELL A?/AU
L28           53 SEA ABB=ON  PLU=ON  MORRELL A?/AU
     TOTAL FOR ALL FILES
L29          237 SEA ABB=ON  PLU=ON  MORRELL A?/AU
L30         2948 SEA ABB=ON  PLU=ON  THOMPSON D?/AU
L31         3971 SEA ABB=ON  PLU=ON  THOMPSON D?/AU
L32         2212 SEA ABB=ON  PLU=ON  THOMPSON D?/AU
L33         4092 SEA ABB=ON  PLU=ON  THOMPSON D?/AU
     TOTAL FOR ALL FILES
L34        13223 SEA ABB=ON  PLU=ON  THOMPSON D?/AU
L35            0 SEA ABB=ON  PLU=ON  L5 AND L10 AND L15 AND L25 AND L30
L36            0 SEA ABB=ON  PLU=ON  L6 AND L11 AND L16 AND L26 AND L31
L37            0 SEA ABB=ON  PLU=ON  L7 AND L12 AND L17 AND L27 AND L32
L38            1 SEA ABB=ON  PLU=ON  L8 AND L13 AND L18 AND L28 AND L33
     TOTAL FOR ALL FILES
L39            1 SEA ABB=ON  PLU=ON  L9 AND L14 AND L19 AND L29 AND L34
L40         4567 SEA ABB=ON  PLU=ON  LI M?/AU
L41         5087 SEA ABB=ON  PLU=ON  LI M?/AU
L42         3613 SEA ABB=ON  PLU=ON  LI M?/AU
L43        15811 SEA ABB=ON  PLU=ON  LI M?/AU
     TOTAL FOR ALL FILES
L44        29078 SEA ABB=ON  PLU=ON  LI M?/AU
L45            0 SEA ABB=ON  PLU=ON  L40 AND L35
L46            0 SEA ABB=ON  PLU=ON  L41 AND L36
L47            0 SEA ABB=ON  PLU=ON  L42 AND L37
L48            1 SEA ABB=ON  PLU=ON  L43 AND L38
     TOTAL FOR ALL FILES
L49            1 SEA ABB=ON  PLU=ON  L44 AND L39
L50            0 SEA ABB=ON  PLU=ON  L45 NOT L4
L51            0 SEA ABB=ON  PLU=ON  L46 NOT L4
L52            0 SEA ABB=ON  PLU=ON  L47 NOT L4
L53            0 SEA ABB=ON  PLU=ON  L48 NOT L4
     TOTAL FOR ALL FILES
```

```
L54           0 SEA ABB=ON  PLU=ON  L49 NOT L4
L55           0 SEA ABB=ON  PLU=ON  L3
L56           0 SEA ABB=ON  PLU=ON  L3
L57           0 SEA ABB=ON  PLU=ON  L3
L58           1 SEA ABB=ON  PLU=ON  L3
     TOTAL FOR ALL FILES
L59           1 SEA ABB=ON  PLU=ON  L4

     FILE 'REGISTRY' ENTERED AT 15:14:49 ON 26 SEP 2007
                E "PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE"/CN 5
L60        1433 SEA ABB=ON  PLU=ON  PYRIDO(L)PYRIMIDINE(L)DIAMINE

     FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 15:16:39 ON 26 SEP 2007
L61          90 SEA ABB=ON  PLU=ON  L60 OR PYRIDO(7A)PYRIMIDINE(5A)DIAMINE
L62         156 SEA ABB=ON  PLU=ON  L60 OR PYRIDO(7A)PYRIMIDINE(5A)DIAMINE
L63         380 SEA ABB=ON  PLU=ON  L60 OR PYRIDO(7A)PYRIMIDINE(5A)DIAMINE
L64         478 SEA ABB=ON  PLU=ON  L60 OR PYRIDO(7A)PYRIMIDINE(5A)DIAMINE
     TOTAL FOR ALL FILES
L65        1104 SEA ABB=ON  PLU=ON  L60 OR PYRIDO(7A) PYRIMIDINE(5A) DIAMINE
L66       26278 SEA ABB=ON  PLU=ON  PDE2 OR PHOSPHODIESTERASE
L67       24560 SEA ABB=ON  PLU=ON  PDE2 OR PHOSPHODIESTERASE
L68       26236 SEA ABB=ON  PLU=ON  PDE2 OR PHOSPHODIESTERASE
L69       27972 SEA ABB=ON  PLU=ON  PDE2 OR PHOSPHODIESTERASE
     TOTAL FOR ALL FILES
L70      105046 SEA ABB=ON  PLU=ON  PDE2 OR PHOSPHODIESTERASE
L71           0 SEA ABB=ON  PLU=ON  L61 AND L66
L72           0 SEA ABB=ON  PLU=ON  L62 AND L67
L73           0 SEA ABB=ON  PLU=ON  L63 AND L68
L74           6 SEA ABB=ON  PLU=ON  L64 AND L69
     TOTAL FOR ALL FILES
L75           6 SEA ABB=ON  PLU=ON  L65 AND L70
                D 1-6 IBIB ABS HITSTR

=> d l3 que stat;d l60 que stat
L1              STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  22

STEREO ATTRIBUTES: NONE
L3            37 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED     121 ITERATIONS                          37 ANSWERS
SEARCH TIME: 00.00.01
```

```
L60         1433 SEA FILE=REGISTRY ABB=ON  PLU=ON  PYRIDO(L)PYRIMIDINE(L)DIAMINE

=> log y

STN INTERNATIONAL LOGOFF AT 15:18:11 ON 26 SEP 2007
```